Related Experiment Video
Updated: Apr 22, 2026

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs
Published on: November 8, 2024
Indication of Adequate Transdermal Fentanyl Dose in Opioid Switching From Oral Oxycodone in Patients With Cancer
Chikako Matsumura1, Masami Yamada2, Saki Fujihara3
1Education and Research Center for Clinical Pharmacy, Kyoto Pharmaceutical University, Kyoto, Japan Department of Pharmacy, Osaka-fu Saiseikai Noe Hospital, Osaka, Japan chika-matsumura@mb.kyoto-phu.ac.jp.
Objective:
The present study aimed to examine affecting factors for conversion ratio and to predict adequate fentanyl dose for patients with cancer pain in opioid switching from oral oxycodone.
Methods:
Patient characteristics, biochemical parameters, daily oxycodone dose, and reasons for opioid switching were retrospectively collected. The effect of variables on the conversion ratio was analyzed by multiple regression analysis.
Results:
Regression analysis for the data from 122 patients suggested that the typical conversion ratio was 95:1; however, this ratio was significantly reduced in patients taking a daily oral morphine-equivalent dose of <45 mg/d and in patients with poor pain control to 52:1 and 64:1, respectively.
Conclusion:
We should carefully and rapidly control pain in opioid switching based on the adequate dose indicated in this study.
More Related Videos
09:54Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
Published on: March 8, 2020
05:23Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread
Published on: July 7, 2023
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
IV Infusion to Oral Dosing: Conversion Methods
Opioid Analgesics: Morphine and Other Natural Cogeners
Analgesia and Pain Management
Drug Dosing: Obese Patients
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...